These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33556381)

  • 1. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study.
    Korobelnik JF; Larsen M; Eter N; Bailey C; Wolf S; Schmelter T; Allmeier H; Chaudhary V
    Am J Ophthalmol; 2021 Jul; 227():106-115. PubMed ID: 33556381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
    Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
    Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
    Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
    Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion - an 18-month prospective cohort study.
    O'Day R; Ali N; Lim LL; Sandhu S; Chau T; Wickremasinghe S
    BMC Ophthalmol; 2020 Feb; 20(1):69. PubMed ID: 32093666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies.
    Feltgen N; Ogura Y; Boscia F; Holz FG; Korobelnik JF; Brown DM; Heier JS; Stemper B; Rittenhouse KD; Asmus F; Ahlers C; Vitti R; Saroj N; Mitchell P
    Ophthalmol Retina; 2019 Jul; 3(7):553-560. PubMed ID: 31277796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
    JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
    Ohji M; Takahashi K; Okada AA; Kobayashi M; Matsuda Y; Terano Y;
    Adv Ther; 2020 Mar; 37(3):1173-1187. PubMed ID: 32016788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
    Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
    Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
    Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
    Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
    Ogura Y; Roider J; Korobelnik JF; Holz FG; Simader C; Schmidt-Erfurth U; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
    Am J Ophthalmol; 2014 Nov; 158(5):1032-8. PubMed ID: 25068637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
    Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
    Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
    Okada AA; Takahashi K; Ohji M; Moon SC; Machewitz T; Sasaki K;
    Adv Ther; 2022 Jun; 39(6):2984-2998. PubMed ID: 35503499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Asia Pac J Ophthalmol (Phila); 2020; 9(1):48-53. PubMed ID: 31990746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
    Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
    J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK;
    JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.